We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
 

Latest News

Metabolomic Characterization of Ovarian Epithelial Carcinomas by HRMAS-NMR Spectroscopy
News   Sep 01, 2011

Metabolomic analysis of intact tissues by HRMAS-NMR spectroscopy was shown to be a promising technique that might be applicable to the therapeutic management of patients.

READ MORE

NIH-funded Researchers Discover Genetic Link to Mesothelioma
News   Aug 31, 2011

Identified gene mutation may underlie other cancer types.

READ MORE

Algeta Signs License with Affibody for Tumor-Targeting Molecules
News   Aug 30, 2011

Algeta gains access to two proprietary Affibody® molecules for use in cancer therapy.

READ MORE

UT Southwestern Research Reveals How Cancer-Driving Enzyme Works
News   Aug 30, 2011

Cancer researchers unlock the cellular-level function of the telomerase enzyme, which is linked to the disease’s growth.

READ MORE

Clavis Pharma Second Quarter and First Half Report 2011
News   Aug 26, 2011

Clavis Pharma and Clovis Oncology expanded the LEAP study, evaluating CP-4126 vs. gemcitabine in pancreatic cancer patients.

READ MORE

FDA Grants Fast Track Designation to Alpharadin
News   Aug 26, 2011

Fast Track designation granted to Alpharadin for the treatment of castration-resistant prostate cancer in patients with bone metastases.

READ MORE

NIH-Funded Study Shows 20 Percent Reduction In Lung Cancer Mortality with Low-Dose CT Compared to Chest X-Ray
News   Aug 24, 2011

Results from the National Lung Screening Trial were published online in the New England Journal of Medicine.

READ MORE

Gladstone Scientists Offer New Insight into the Regulation of Stem Cells and Cancer Cells
News   Aug 23, 2011

Breakthrough discovery is likely to advance medicine and human health.

READ MORE

Immunogene Therapy Combined with Standard Treatment is Safe for Patients with Brain Tumors
News   Aug 23, 2011

The findings suggest that the therapy might also stimulate an immune response against the tumor.

READ MORE

Key European Patent Granted for MolMed's TK Cell Therapy
News   Aug 19, 2011

MolMed's investigational cell therapy product currently in Phase III for the treatment of high-risk leukaemia.

READ MORE

 
Advertisement